Visit https://www.peervoice.com/DZZ860 to view the entire programme with slides. After completing “Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses”, participants will be able to: Summarise the latest clinical evidence for managing patients with NSCLC with MET exon 14 (METex14) skipping mutations: Describe the strengths and limitations of these data within the context of current clinical practice; Discuss how these data may be applied to current clinical practice.